| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03396861 Details | 2020-08-21 Interventional | 1 | 1 | Aflibercept Macular Edema Irvine-Gass Syn… | Low enrollment - | |||
| NCT03000660 Details | 2020-08-21 Interventional | 1 | 3 | Dexamethasone Venetoclax Amyloidosis Immunoglobulin … AL Amyloidosis | partial clinical hold per FDA - | |||
| NCT04520620 2020-001823-15 Details | 2020-08-20 Interventional | 4 | 0 | Enoxaparin Sars-CoV2 | End of the COVID 19 epidemic in the region and decision to participate in a national study on
the same subject (COVI-DOSE). - | |||
| NCT01866917 Details | 2020-08-20 Interventional | 1/2 | 35 | Ropivacaine Pain | Pharmacy stopped dispensing study medication Limitations of this study include interim analysis with limited sample size, thus it may result in inadequate power. Early termination due to pharmacist refusal to dispense the experimental Rx (no AEs/SAEs recorded). Only an abstract was written. | |||
| NCT01302613 Details | 2020-08-20 Interventional | 1/2 | 0 | Capecitabine Leucovorin Oxaliplatin Adenocarcinoma Rectal Neoplasm… Stage II Rectal… Stage III Recta… | Drug shortage - | |||
| NCT00914940 Details | 2020-08-20 Interventional | 2 | 41 | Fludarabine Fludarabine pho… Tacrolimus Thiotepa Graft vs Host D… Leukemia Myelodysplastic… Preleukemia Syndrome Graft Versus Ho… | Did not reach one of the primary endpoints of decreased total acute GVHD - | |||
| NCT00513552 Details | 2020-08-20 Interventional | 4 | 0 | Clarithromycin Clofazimine Rifabutin Crohn Disease Mycobacterium a… Paratuberculosi… Crohn's Disease | No patient - | |||
| NCT04398290 Details | 2020-08-19 Interventional | 2 | 0 | Nitric Oxide COVID-19 Hypoxia Respiratory Ins… Hypoxemia Hypoxemic Respi… | IRB AND FDA REVIEWS DEFERRED - | |||
| NCT04360759 Details | 2020-08-18 Interventional | 3 | 0 | Chloroquine Hydroxychloroqu… COVID-19 Covid-19 HIV | Equipoise for hydroxychloquine was lost - | |||
| NCT04273191 Details | 2020-08-18 Interventional | 4 | 0 | Brexanolone Depression Depression, Pos… Depressive Diso… Postpartum Depr… | Sage Therapeutics has decided not to proceed with this study at this time - | |||
| NCT03679975 Details | 2020-08-18 Interventional | 2 | 9 | Riluzole Amyotrophic Lat… Motor Neuron Di… Sclerosis | The study is no longer required - | |||
| NCT02326844 Details | 2020-08-18 Interventional | 2 | 3 | Talazoparib Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | Study was closed by the Cancer Therapy Evaluation Program (CTEP) - | |||
| NCT00789464 Details | 2020-08-18 Interventional | 2 | 0 | Sulfamethoxazol… Trimethoprim Communicable Di… Infections Urinary Tract I… Recurrent Urina… | Withdrawn by PI - | |||
| NCT00006472 Details | 2020-08-18 Interventional | 2 | 4 | Carboplatin Fluorouracil Paclitaxel Esophageal Neop… Esophageal Canc… | - - | |||
| NCT03488810 Details | 2020-08-17 Interventional | 3 | 0 | Androgen Antago… Androgens Hormones Nonsteroidal An… Prostatic Neopl… Prostate Cancer | Extended study timelines and additional budget could no longer be supported. - | |||
| NCT03413891 Details | 2020-08-17 Interventional | 4 | 222 | Tranexamic Acid Hemorrhage Tooth Extractio… | Advice from DSMB - | |||
| NCT00825123 Details | 2020-08-17 Interventional | 4 | 2 | Metoprolol Central Arteria… | - - | |||
| NCT02875067 Details | 2020-08-14 Interventional | 1/2 | 6 | Lenalidomide Pembrolizumab Hodgkin Disease Lymphoma Relapsed Hodgki… Relapsed Non-Ho… | Merck's decision for early termination of the data - | |||
| NCT00330668 2019-000844-81 Details | 2020-08-14 Interventional | 3 | 114 | Mecasermin Failure to Thri… Growth Disorder… | Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day The study was terminated by the sponsor due to an unacceptably high incidence of hypoglycaemia observed in approximately 50% of the subjects receiving 200 μg/kg rhIGF-1 or greater QD. | |||
| NCT03598816 Details | 2020-08-13 Interventional | 2 | 0 | Durvalumab Tremelimumab Carcinoma Carcinoma, Rena… Renal Cell Carc… | FDA Contingencies unresolved - |